FrancophonIA/ELRC3.0 huggingface dataset:
English: In addition, the failure of the HPS2-THRIVE study to meet the primary efficacy endpoints raised serious concerns regarding the efficacy of nicotinic acid/laropiprant in the indicated patient population, as overlap between this and the study populations is expected.
Estonian: Peale selle tõstatas esmase efektiivsuse tulemusnäitaja mittesaavutamine HPS2THRIVE uuringus tõsiseid küsimusi nikotiinhappe/laropiprandi efektiivsuse kohta patsientide populatsioonis, kellel ravim on praegu näidustatud, sest võib eeldada selle kattumist antud uuringu populatsiooniga.
English: • The CHMP considered that the failure of the HPS2-THRIVE study to meet the primary efficacy endpoints raises serious concerns regarding the efficacy of laropiprant/nicotinic acid,
Estonian: • inimravimite komitee leidis, et esmase efektiivsuse tulemusnäitaja mittesaavutamine HPS2THRIVE uuringus tõstatas tõsiseid küsimusi nikotiinhappe/laropiprandi efektiivsuse kohta;
English: Based on the known safety profile of the product, some adverse events were expected, such as elevations in transaminases, myopathy, some skin and gastrointestinal events and impaired glucose tolerance.
Estonian: Nikotiinhappe/laropiprandi teadaolevat ohutusprofiili arvestades oli mõnede nimetatud kõrvalnähtude esinemine oodatav, näiteks transaminaaside sisalduse suurenemine, müopaatia, mõned naha ja seedetraktiga seotud toimed ning glükoositaluvuse halvenemine.
English: The risk of blood and lymphatic disorders was greater in the study drug group compared to the placebo group.
Estonian: Vere ja lümfisüsteemi häirete risk oli uuringuravimi rühmas suurem kui platseeborühmas.
English: The CHMP therefore concluded that the benefit-risk balance of nicotinic acid/laropiprant is affected adversely by the results from the HPS2-THRIVE study and is considered no longer favourable.
Estonian: Ülaltoodut arvesse võttes otsustas inimravimite komitee, et HPS2-THRIVE uuringu tulemused mõjutavad ebasoodsas suunas nikotiinhappe/laropiprandi kasulikkuse ja riski tasakaalu ning seda ei saa enam pidada positiivseks.
English: • The CHMP therefore considered that a patient population in which nicotinic acid/laropiprant has a clear favourable benefit-risk cannot be identified based on the current data.
Estonian: • seetõttu otsustas inimravimite komitee, et olemasolevate andmete alusel ei ole võimalik kindlaks määrata patsientide populatsiooni, kellel nikotiinhappe/laropiprandi kasulikkuse ja riski tasakaal oleks selgelt positiivne.
English: The PRAC therefore considered that the results demonstrate that nicotinic acid/laropiprant has no additional efficacy in terms of cardiovascular outcome as an add-on treatment to statins.
Estonian: Seetõttu otsustas ravimiohutuse järelevalve riskihindamise komitee, et täiendava ravi korral lisaks satiinidele ei näidanud uuringu tulemused nikotiinhappe/laropiprandi lisaefektiivsust kardiovaskulaarsete ravitulemite osas.
English: To lift the suspension, the MAH would need to provide convincing data to identify a patient population in which the efficacy of nicotinic acid/laropiprant can be demonstrated, and in which the benefit clearly outweighs the risks, taking into account the new risks identified by the HPS2-THRIVE study (see Annex II).
Estonian: Müügiloa peatamise tühistamiseks peab müügiloa hoidja esitama veenvad andmed patsientide populatsiooni kohta, kellel nikotiinhappe/laropiprandi efektiivsus on tõendatud ja kellel ravimi kasulikkus kaalub selgelt üles võimalikud riskid, võttes arvesse ka uusi riske, mis tehti kindlaks HPS2THRIVE uuringus (vt II lisa).
English: There was a statistically significant increase in the incidence of non-fatal serious adverse events in the nicotinic acid/laropiprant (study drug) group compared to the placebo group.
Estonian: Nikotiinhappe/laropiprandirühmas (uuringuravim) esines platseeborühmaga võrreldes statistiliselt oluline mittefataalsete tõsiste kõrvalnähtude esinemissageduse suurenemine.
English: For the suspension to be lifted, the MAH would need to provide convincing data to identify a patient population in which the efficacy of nicotinic acid/laropiprant can be demonstrated, and in which the benefit clearly outweighs the risks, taking into account the new risks identified by the HPS2-THRIVE study.
Estonian: Müügiloa peatamise tühistamiseks peab müügiloa hoidja esitama veenvad andmed patsientide populatsiooni kohta, kellel nikotiinhappe/laropiprandi efektiivsus on tõendatud ja kellel ravimi kasulikkus kaalub selgelt üles võimalikud riskid, võttes arvesse ka uusi riske, mis tehti kindlaks HPS2THRIVE uuringus.
English: • The CHMP concluded that the statistically significant increase in the incidence of serious adverse events observed in the nicotinic acid/laropiprant group compared to the placebo group of the HPS2-THRIVE study raises serious concerns,
Estonian: • inimravimite komitee arvates tõstatab HPS2-THRIVE uuringus nikotiinhappe-/laropiprandirühma ja platseeborühma võrdlemisel täheldatud statistiliselt oluline tõsiste kõrvalnähtude esinemissageduse suurenemine tõsiseid ohutusküsimusi;
English: International Non-Proprietary Name (INN): paroxetine
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): paroksetiin
English: The final opinion was converted into a Decision by the European Commission on 29 March 2005.
Estonian: See lõppotsus kinnitati Euroopa Komisjoni otsusena 29. märtsil 2005.
English: Written explanations were provided by the Marketing Authorisation Holder by 1 September 2003, 13 February 2004, 2 April 2004 and 16 April 2004.
Estonian: Müügiloa hoidja esitas kirjalikud selgitused 1. septembriks 2003, 13. veebruariks 2004, 2. aprilliks 2004 ja 16. aprilliks 2004.
English: Oral explanations were given on 20 April
Estonian: Suulised selgitused esitati 20. aprillil 2004.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE OPINION FOLLOWING AN ARTICLE 31 REFERRAL
Estonian: INIMTERVISHOIUS KASUTATAVATE RAVIMITE KOMITEE ARVAMUS PÄRAST ARTIKLI 31 JÄRGSET ESILDIST
English: Paroxetine was first approved in 1990 as an antidepressant in the U.K.
Estonian: Paroksetiin kiideti esmakordselt heaks antidepressandina Suurbritannias 1990. aastal.
English: - Panic disorder with and without agoraphobia
Estonian: - Paanikahäire agorafoobiaga või ilma selleta
English: On 13 June 2003, UK referred the matter to the EMEA under Article Article 31 of Directive 2001/83/EC, as amended, for paroxetine containing medicinal products.
Estonian: Ühendkuningriik suunas küsimuse EMEA-le 13. juunil 2003. a direktiivi 2001/83/EÜ artikli 31 kohaselt muudatuse tegemiseks paroksetiini sisaldavate ravimpreparaatide kohta.
English: The referral procedure started on 26 June 2003.
Estonian: Esildist hakati menetlema 26. juunil 2003 aastal.
English: Notes: The information given in this document and Annexes reflect only the CHMP Opinion dated 8 December 2004.
Estonian: * Märkused: Selles dokumendis ja lisades sisalduv teave kajastavad ainult inimtervishoius kasutavate ravimite komitee 8. detsembri 2004. a arvamust.
English: For more information please refer to: http://www.emea.eu.int/pdfs/human/referral/SSRIs/29783705en.pdf http://www.emea.eu.int/pdfs/human/referral/SSRIs/EMEA-H-A-31-651-SSRIs-en.pdf
Estonian: Lisateavet vt: http://www.emea.eu.int/pdfs/human/referral/SSRIs/29783705en.pdf http://www.emea.eu.int/pdfs/human/referral/SSRIs/EMEA-H-A-31-651-SSRIs-en.pdf
English: 29 March 2005 CHMP/187488/2004
Estonian: 29. märts 2005 CHMP/187488/2004
English: Paroxetine
Estonian: Paroksetiin
English: - Post-traumatic stress disorder
Estonian: - Post-traumaatiline stressihäire
English: Paroxetine inhibits the neuronal uptake of serotonin and thereby facilitates serotonergic transmission.
Estonian: Paroksetiin inhibeerib serotoniini neuronaalset tagasihaaret ja soodustab sellega serotonergilist erutuse edastamist.
English: The Rapporteur and Co-Rapporteur appointed were: Dr. F. Lekkerkerker and Dr. P. Arlett, respectively.
Estonian: Ettekandjaks ja kaasettekandjaks määrati vastavalt Dr. F. Lekkerkerker ja Dr. P. Arlett.
English: Subsequently national Marketing Authorisations have been granted in all EU Member States for the treatment of various psychiatric disorders.
Estonian: Järgnevalt on paroksetiin kõigis EL liikmesriikides heaks kiidetud erinevate psühhiaatriliste häirete raviks.
English: During the referral procedure Dr. B. van Zwieten Boot took over the Rapporteurship from Dr. F. Lekkerkerker and Dr. F. Rotblat took over from Dr. P. Arlett.
Estonian: Esildise menetluse ajal võttis dr. B. van Zwieten Boot ettekandja kohustused üle dr. F. Lekkerkerker'ilt ja dr. F. Rotblat dr. P. Arlett'ilt.
English: The list of product names concerned is given in the Annex I. The scientific conclusions are provided in the Annex II, together with the amended Summary of Product Characteristics in the Annex III and the conditions of the marketing authorisations in the Annex IV.
Estonian: Teaduslikud järeldused on välja toodud II lisas, toote omaduste muudetud kokkuvõte III lisas ja müügiloa tingimused IV lisas.
English: The reasons for referral concerned the risk of emotional lability, including hostility and suicidal behaviour in children and adolescents and withdrawal reactions with paroxetine.
Estonian: Esildise põhjuseks olid paroksetiiniga seotud emotsionaalne labiilsus, sh vaenulikkus ja suitsiidikäitumine lastel ja noorukitel ning võõrutusnähtude ohud.
English: An updated warning in relation to children and adolescents was recommended to be included in the Product Information.
Estonian: Tooteinfosse soovitati lisada lapsi ja noorukeid puudutav ajakohastatud hoiatus.
English: Following the adoption of the CHMP Opinion for paroxetine, the CHMP further reviewed the risk of suicidal behaviour in children and adolescents treated with this type of medicines.
Estonian: Pärast paroksetiini käsitleva arvamuse vastuvõtmist vaatas CHMP täiendavalt läbi sama tüüpi ravimitega ravitud laste ja noorukite suitsiidikäitumisega seotud ohud.
English: Paroxetine is a phenylpiperidine derivative and is a selective inhibitor of the presynaptic 5hydroxytryptamine (5-HT) reuptake.
Estonian: Paroksetiin on fenüülpiperidiini derivaat ning tugev ja selektiivne presünaptilise 5hüdroksütrüptamiini (5-HT) tagasihaarde inhibiitor.
English: Based on evaluation of the available data and the Rapporteurs' assessment reports, the CHMP considered that the benefit/risk profile of paroxetine containing medicinal products remains favourable.
Estonian: Kättesaadavate andmete ja ettekandjate hindamisaruannete põhjal leidis inimtervishoius kasutavate ravimite komitee, et paroksetiini sisaldavate ravimpreparaatide kasulikkuse ja riski suhe on jätkuvalt soodne.
English: BACKGROUND INFORMATION*
Estonian: TAUSTATEAVE*
English: - Obsessive compulsive disorder
Estonian: - Obsessiiv-kompulsiivne häire
English: - Major depressive episode
Estonian: - Raske depressiivne episood
English: Paroxetine containing medicinal products are approved for the treatment of:
Estonian: Paroksetiini sisaldavate ravimpreparaadid on näidustatud järgmiste seisundite raviks:
English: The CHMP adopted an opinion on 22 April 2004.
Estonian: Inimtervishoius kasutavate ravimite komitee võttis hinnagu vastu 22. aprillil 2004.
English: - Generalised anxiety disorder
Estonian: - Generaliseerinud ärevushäire
English: - Social anxiety disorders / social phobia
Estonian: - Sotsiaalne ärevushäire
English: The final CHMP opinion was adopted on 8 December 2004 recommending the variation of the Marketing Authorisations in accordance with the Summary of Product Characteristics for paroxetine containing medicinal products.
Estonian: Lõplik inimtervishoius kasutavate ravimite komitee hinnang võeti vastu 8. detsembril 2004, soovitades:
English: This summary was last updated in 09/2013.
Estonian: Kokkuvõtte viimane uuendus: 09/2013.
English: The full EPAR for Inflectra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Inflectra kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: A risk management plan has been developed to ensure that Inflectra is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Inflectra võimalikult ohutu kasutamine.
English: Some side effects, including infections, may be more common in children than in adults.
Estonian: Mõni kõrvalnäht, sealhulgas infektsioonid, võib esineda lastel sagedamini kui täiskasvanutel.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Inflectra on 10 September 2013.
Estonian: Euroopa Komisjon andis Inflectra müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 10. septembril 2013.
English: The company will also carry out studies to confirm the long-term safety of the medicine.
Estonian: Ka korraldab ettevõte ravimi pikaajalise ohutuse tõendamise uuringud.
English: It is usually used when other medicines or treatments have failed, in adults with the following diseases:
Estonian: Seda kasutatakse tavaliselt juhul, kui muud ravimid või raviviisid on osutunud ebaefektiivseks, järgmiste haiguste raviks täiskasvanutel:
English: What measures are being taken to ensure the safe and effective use of Inflectra?
Estonian: Mis meetmed võetakse, et tagada Inflectra ohutu ja efektiivne kasutamine?
English: What is Inflectra and what is it used for?
Estonian: Mis on Inflectra ja milleks seda kasutatakse?
English: Other information about Inflectra
Estonian: Muu teave Inflectra kohta
English: Why is Inflectra approved?
Estonian: Miks Inflectra heaks kiideti?
English: The dose is 5 mg per kilogram for the other diseases.
Estonian: Muude haiguste korral on annus 5 mg/kg.
English: The Committee recommended that Inflectra be approved for use in the EU.
Estonian: Komitee soovitas Inflectra kasutamise Euroopa Liidus heaks kiita.
English: To reduce the risk of infusion-related reactions, patients may be given other medicines before or during treatment with Inflectra or the infusion time may be slowed down.
Estonian: Infusioonireaktsioonide riski vähendamiseks tohib patsientidele anda enne ravi Inflectraga või ravi ajal muid ravimeid, samuti tohib infusiooni aeglustada.
English: Inflectra is given as an infusion lasting one or two hours.
Estonian: Inflectrat manustatakse 1 või 2 tundi kestva infusioonina.
English: Inflectra is usually given as 3 mg per kilogram body weight in rheumatoid arthritis, although the dose can be increased if necessary.
Estonian: Reumatoidartriidi raviks manustatakse Inflectrat tavaliselt 3 mg kehamassi kilogrammi kohta, kuid vajaduse korral tohib annust suurendada.
English: Inflectra was compared with Remicade in one main study involving 606 adult patients with rheumatoid arthritis.
Estonian: Inflectrat võrreldi Remicadega ühes põhiuuringus, milles osales 606 reumatoidartriidiga täiskasvanud patsienti.
English: The most common side effects with Inflectra (seen in more than 1 patient in 10) are viral infections (such as flu or cold sores), headache, upper respiratory-tract infection (colds), sinusitis (inflammation of the sinuses), nausea (feeling sick), abdominal pain (stomach ache), infusion-related reactions and pain.
Estonian: Inflectra kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on on viirusinfektsioonid (nt gripp või vöötohatis), peavalu, ülemiste hingamisteede infektsioonid (külmetused), sinusiit (põskkoopapõletik), iiveldus, kõhuvalu, infusiooniga seotud reaktsioonid ja valu.
English: Patients who receive Inflectra must be given a special alert card that summarises the safety information about the medicine.
Estonian: Inflectrat saavatele patsientidele tuleb anda spetsiaalne hoiatuskaart, millel on ravimi kokkuvõtlik ohutusteave.
English: What are the risks associated with Inflectra?
Estonian: Mis riskid Inflectraga kaasnevad?
English: An additional study was also carried involving 250 patients with ankylosing spondylitis out to show that Inflectra produces levels of the active substance in the body that are comparable to the reference medicine, Remicade.
Estonian: Samuti korraldati lisauuring, milles osales 250 anküloseeriva spondüliidiga patsienti, et tõendada, et Inflectra tekitab organismis toimeainesisalduse, mis on võrreldav võrdlusravimi Remicade tekitatavaga.
English: This means that Inflectra is similar to a biological medicine (the ‘reference medicine') that is already authorised in the European Union (EU) and that Inflectra and the reference medicine contain the same active substance.
Estonian: See tähendab, et Inflectra on sarnane bioloogilise ravimiga (võrdlusravimiga), millel juba on Euroopa Liidus müügiluba ning mis sisaldab sama toimeainet.
English: Inflectra is also used in patients aged between six and 17 years with severe, active Crohn's disease or severely active ulcerative colitis, when they have not responded to or cannot take other medicines or treatments.
Estonian: Inflectrat kasutatakse ka 6-17-aastastel patsientidel, kellel on raske aktiivne Crohni tõbi või raske aktiivne haavandiline koliit, kui teised ravimid ei ole tekitanud neil ravivastust või nad ei saa teisi ravimeid või raviviise kasutada.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that, in accordance with EU requirements, Inflectra has been shown to have a comparable quality, safety and efficacy profile to Remicade.
Estonian: Inimravimite komitee otsustas, et Euroopa Liidu nõuete kohaselt on tõendatud, et Inflectra kvaliteedi, ohutuse ja efektiivsuse profiil on võrreldav võrdlusravimi Remicade profiiliga.
English: Therefore, the CHMP's view was that, as for Remicade, the benefit outweighs the identified risks.
Estonian: Seetõttu oli inimravimite komitee arvamusel, et nagu ka Remicade korral, ületab Inflectra kasulikkus sellega kaasnevad riskid.
English: Inflectra infliximab
Estonian: Inflectra infliksimaab
English: After 30 weeks of treatment Inflectra was as effective as Remicade with around 60 % of patients responding to treatment with either medicine.
Estonian: Pärast 30-nädalast ravi oli Inflectra sama efektiivne kui Remicade ja patsiente, kellel tekkis ühele või teisele ravimile ravivastus, oli ligikaudu 60%.
English: Inflectra was studied to show that it is comparable to the reference medicine, Remicade.
Estonian: Inflectrat uuriti, et näidata selle võrreldavust võrdlusravimiga Remicade.
English: Patients received either Inflectra or Remicade in addition to methotrexate for 30 weeks.
Estonian: Patsiendid said 30 nädala jooksul lisaks metotreksaadile kas Inflectrat või Remicadet.
English: In addition, the company that markets Inflectra will provide educational material to doctors who are expected to prescribe the medicine in adults and children including information on the safety of the medicine and an alert card to be given to patients.
Estonian: Lisaks varustab Inflectrat turustav ettevõte kõik ravimit täiskasvanutele ja lastele eeldatavasti määravad arstid ravimiohutuse teabega ning patsienti hoiatuskaardiga.
English: This is a summary of the European public assessment report (EPAR) for Inflectra.
Estonian: See on ravimi Inflectra Euroopa avaliku hindamisaruande kokkuvõte.
English: Inflectra must not be used in patients who have experienced hypersensitivity (allergy) to infliximab in the past, or who are hypersensitive (allergic) to mouse proteins or any of the other ingredients of Inflectra.
Estonian: Inflectrat ei tohi kasutada patsiendid, kellel on esinenud infliksimaabi suhtes ülitundlikkus (allergia) või kes on hiirevalkude või Inflectra mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: It is not intended to provide practical advice on how to use Inflectra.
Estonian: Hindamisaruandes ei anta Inflectra kasutamise praktilisi nõuandeid.
English: By blocking TNF-alpha, infliximab improves the inflammation and other symptoms of the diseases.
Estonian: TNF-α blokeerimisega leevendab infliksimaab põletikku ja muid haigussümptomeid.
English: Inflectra is an anti-inflammatory medicine that contains the active substance infliximab.
Estonian: Inflectra on põletikuvastane ravim, mis sisaldab toimeainena infliksimaabi.
English: How is Inflectra used?
Estonian: Kuidas Inflectrat kasutatakse?
English: For more information about treatment with Inflectra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Inflectraga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For practical information about using Inflectra, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Inflectra kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Inflectra is used to treat.
Estonian: See virgatsaine osaleb põletiku tekitamisel ning selle sisaldus on suur patsientidel, kelle haigusi ravitakse Inflectraga.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Inflectra, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Inflectra ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavate ettevaatusmeetmete teave.
English: It can only be obtained with a prescription and treatment should be started and supervised by a specialised doctor who has experience in the diagnosis and treatment of the diseases that Inflectra can be used to treat.
Estonian: Ravi peab alustama ja jälgima eriarst, kes on kogenud nende haiguste diagnoosimises ning ravis, mille vastu Inflectrat kasutatakse.
English: • Crohn's disease (a disease causing inflammation of the digestive tract), when the disease is moderate to severe or fistulising (with the formation of fistulae, abnormal passageways between the gut and other organs);
Estonian: • Crohni tõbi (seedetrakti põletikku põhjustav haigus), kui haigus on mõõdukas kuni raske või tekitab fistuleid (uurised ehk soole ja muude elundite vahelised ebanormaalsed ühendused);
English: ‘Inflectra is a ‘biosimilar' medicine.
Estonian: Inflectra on bioloogiliselt sarnane ravim.
English: What benefits of Inflectra have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Inflectra kasulikkus?
English: Inflectra must not be used in patients with tuberculosis, other severe infections, or moderate or severe heart failure (an inability of the heart to pump enough blood around the body).
Estonian: Inflectrat ei tohi kasutada patsiendid, kellel on tuberkuloos, muud rasked infektsioonid või mõõdukas või raske südamepuudulikkus.
English: For the full list of all side effects reported with Inflectra, see the package leaflet.
Estonian: Inflectra kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) in the body.
Estonian: Inflectra toimeaine infliksimaab on monoklonaalne antikeha (teatud valk), mis tunneb ära organismis leiduva teatud aine (antigeeni) ja seondub sellega.
English: See the summary of product characteristics (also part of the EPAR) for full details.
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes (samuti Euroopa avaliku hindamisaruande osa).
English: The infliximab is made by cells that have received a gene (DNA), which makes them able to produce it.
Estonian: Inflectrat valmistatakse rekombinant-DNA-tehnika abil: infliksimaabi toodavad rakud, millesse on lisatud selle teket võimaldav geen (DNA).
English: Infliximab has been designed to attach to a chemical messenger in the body called tumour necrosis factor-alpha (TNF-alpha).
Estonian: Infliksimaab seondub spetsiifiliselt organismis sisalduva virgatsainega kasvaja α-nekroositeguriga (TNF-α).
English: Inflectra is available as a powder to be made up into a solution for infusion (drip) into a vein.
Estonian: Inflectrat turustatakse infusioonilahuse (veeni tilgutatava lahuse) pulbrina.